Trial ID or NCT#

NCT02298348

Status

NOT RECRUITING

Purpose

This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigators first need to find out the highest dose of sorafenib that can be given safely together with cyclophosphamide and topotecan. This is the first study to test giving these three drugs together and will help determine the highest dose of sorafenib that can safely be given together with cyclophosphamide and topotecan to patients with resistant/relapsed neuroblastoma.

Official Title

NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

Eligibility Criteria

Ages Eligible for Study: Younger than 30 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Contact us to find out if this trial is right for you.

CONTACT

Spectrum Child Health
(650) 724-1175